A detailed history of Nordea Investment Management Ab transactions in Alector, Inc. stock. As of the latest transaction made, Nordea Investment Management Ab holds 157,742 shares of ALEC stock, worth $402,242. This represents 0.0% of its overall portfolio holdings.

Number of Shares
157,742
Previous 159,999 1.41%
Holding current value
$402,242
Previous $726,000 1.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$4.34 - $6.58 $9,795 - $14,851
-2,257 Reduced 1.41%
157,742 $736,000
Q2 2024

Aug 08, 2024

SELL
$4.19 - $6.23 $120,537 - $179,224
-28,768 Reduced 15.24%
159,999 $726,000
Q1 2024

May 02, 2024

SELL
$5.69 - $8.08 $8,665 - $12,305
-1,523 Reduced 0.8%
188,767 $1.14 Million
Q4 2023

Jan 10, 2024

SELL
$3.77 - $8.39 $46,812 - $104,178
-12,417 Reduced 6.13%
190,290 $1.52 Million
Q3 2023

Nov 13, 2023

BUY
$5.2 - $8.77 $358 - $605
69 Added 0.03%
202,707 $1.31 Million
Q2 2023

Jul 07, 2023

BUY
$5.86 - $7.93 $345,845 - $468,012
59,018 Added 41.09%
202,638 $1.22 Million
Q1 2023

Apr 19, 2023

SELL
$5.85 - $9.84 $153,544 - $258,270
-26,247 Reduced 15.45%
143,620 $889,000
Q4 2022

Feb 08, 2023

SELL
$6.88 - $9.55 $74,159 - $102,939
-10,779 Reduced 5.97%
169,867 $1.57 Million
Q3 2022

Oct 19, 2022

SELL
$8.19 - $13.2 $18,394 - $29,647
-2,246 Reduced 1.23%
180,646 $1.79 Million
Q2 2022

Aug 09, 2022

BUY
$7.65 - $14.24 $41,302 - $76,881
5,399 Added 3.04%
182,892 $1.81 Million
Q1 2022

Apr 11, 2022

BUY
$13.02 - $20.78 $2.06 Million - $3.28 Million
158,066 Added 813.64%
177,493 $2.61 Million
Q4 2021

Jan 20, 2022

BUY
$19.35 - $25.54 $375,912 - $496,165
19,427 New
19,427 $417,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $211M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Nordea Investment Management Ab Portfolio

Follow Nordea Investment Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nordea Investment Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Nordea Investment Management Ab with notifications on news.